{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"Best ORR (complete response (CR) + partial response \\[PR\\]) by Independent Radiology Committee (IRC) based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification. A participant will be assumed as a responder if he/she achieves complete or partial response at any postbaseline visit.","groups":[{"description":"Cohort 1: 200 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"OG000","title":"Safety run-in Cohort 1"},{"description":"Cohort 2: 300 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"OG001","title":"Safety run-in Cohort 2"},{"description":"Cohort 3: 200 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"OG002","title":"Safety run-in Cohort 3"},{"description":"Cohort 4: 300 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"OG003","title":"Safety run-in Cohort 4"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Safety Run In Set (SRI) consists of all subjects of the 4 safety run-in cohorts who have received at least 66% of the combination dose during Cycle 1.","reportingStatus":"POSTED","timeFrame":"Disease assessments were conducted on Day 43 (+- 3 days) of each cycle. All subjects were treated for a maximum of 3 cycles.","title":"Objective Response Rate (ORR) by Independent Radiology Committee","type":"PRIMARY","unitOfMeasure":"Participants"}